American Academy of Orthopedic Surgeons. Treatment of Osteoarthritis of the Knee 2nd edition. 2011; Available at: https://www.ncbi.nlm.nih.gov/pubmed/23996988 Accessed 02/14/2019.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. Washington, DC, American Psychiatric Association. 2013 page 541.
PCSS-MAT/APA. Opioid use disorder diagnostic criteria. Reprinted from Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, (Copyright 2013) American Psychiatric Association. Available at: https://pcssnow.org/resource/opioid-use-disorder-opioid-addiction/ Accessed 02/14/2019.
Babor TF, de la Fluente JF, Saunders J, Grant M. AUDIT: The Alcohol Use Disorders Identification Test: guidelines for use in primary health care. Generva, Switzerland: World Health Organization. 1992.
Beck AT, Steer RA, Carbin MG. Psychometric properties of the Beck Depression Inventory: Twenty-five years of evaluation. Clinical Psychology Review. 1988; 8(1):77-100.
Belgrade M, Schamber CD, Lindgren BR. The DIRE score. Predicting outcomes of opioid prescribing for chronic pain. The Journal of Pain. 2006; 7(9): 671-81. Available at: http://www.jpain.org/article/S1526-5900(06)00626-2/abstract. Accessed 02/14/2019.
Briley M, Moret C. Treatment of comorbid pain with serotonin norepinephrine reuptake inhibitors. CNS Spectr. 2008; 13(7): 22-26.
Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain — United States, 2016. MMWR Recomm Rep. 2016; ePub: March 2016: DOI: http://dx.doi.org/10.15585/mmwr.rr6501e1er. Available at: https://www.cdc.gov/mmwr/volumes/65/rr/rr6501e1.htm. Accessed 02/14/2019.
FDA. Drug Safety and Availability – FDA Drug Safety Communication: FDA recommends against the continued use of propoxyphene. https://www.fda.gov/Drugs/DrugSafety/ucm234338.htm. Accessed 02/14/2019.
Kellgren JH, Lawrence JS. Radiological assessment of osteo-arthrosis. Ann. Rheum. Dis. 2000;16 (4): 494-502. Available at https://www.ncbi.nlm.nih.gov/pubmed/13498604. Accessed 02/14/2019.
Krebs EE, Lorenz KA, Bair MJ. Development and initial validation of the PEG, a three-item scale assessing pain intensity and interference. J Gen Intern Med. 2009; 24(6): 733-738. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686775/ Accessed 02/14/2019.
Kumar L, Barker C, Emmanuel A. Opioid-induced constipation: Pathophysiology, clinicial consequences, and management. Gastroenterology Research and Practice. 2014; 2014. Available at: https://www.hindawi.com/journals/grp/2014/141737/ Accessed 02/14/2019.
Marshall, PS. Physical Functional Ability Questionnaire (FAQ5). In: Assessment and Management of Chronic Pain, 5th edition. Institute for Clinical Systems Improvement. 2011; 14: Appendix C:99. Available at: http://www.generationsprimarycare.com/assets/pain-contract.pdf Accessed 02/14/2019.
Merrill JO, Von Korff M, Banta-Green CJ, et al. Prescribed opioid difficulties, depression and opioid dose among chronic opioid therapy patients. General Hospital Psychiatry. 2012; 34: 581-587. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22959422 Accessed 02/14/2019.
Pani PP, Vacca R, Troqu E, Amato L, Davoli M. Pharmacological treatment for depression during opioid agonist treatment for opioid dependence. Cochrane Database of Systematic Reviews. 2010; 8(9): CD008373. Available at: https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008373.pub2/abstract Accessed 02/14/2019.
Passik SD, Kirsh KL, Casper D. Addiction-related assessment tools and pain management: instruments for screening, treatment planning and monitoring compliance. Pain Med. 2008; 9: S145-S166.
Webster LR. Predicting aberrant behaviors in opioid-treated patients: Preliminary validation of the opioid risk tool. Pain Medicine. 2005;6(6):432-442. Available at: https://www.ncbi.nlm.nih.gov/pubmed/16336480 Accessed 02/14/2019.
